BrainStorm Announces ALS Clinical Trial Results

Most patients in a recently concluded clinical trial displayed improvement in the form of slower progression of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's Disease), according to an Israeli company based in Petach Tikva. BrainStorm Cell Therapeutics, Inc., is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases.

BrainStorm revealed the results from a clinical trial for its stem cell treatment of ALS, a neurodegenerative disease that affects 5,600 people in the U.S. alone. The company